Company intelligence / Profile preview

Ethical Oncology Science

Ownership: Private
Development stage: Other

Overview

Lucitanib, the lead program, demonstrated a promising response rate (~50%) in heavily pre-treated FGF-aberrant breast cancer patients and showed activity in other tumor types. The median progression-free survival was reported as 9.4 months in a subset of these patients. The safety profile was consistent with VEGF inhibitors, with common adverse events including hypertension and proteinuria.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Servier

Beyond the preview

Go deeper on Ethical Oncology Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ethical Oncology Science.

Explore the full profile